Precision for Value’s Jeremy Schafer highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Precision for Value’s Jeremy Schafer discusses safety concerns over some hepatitis C drugs in the latest edition of Drug Topics.
Life Sciences Companies Now Given Unprecedented Access and Visualization of Quality Performance Data
JOINT PRESS RELEASE
February 8, 2017 – New York, NY – Life sciences companies stand to be the primary beneficiary of a unique license agreement that integrates the industry’s most robust quality performance data available into a single tool. Precision for Value (PFV) has entered into an arrangement with the National Committee for Quality Assurance (NCQA) to incorporate the Healthcare Effectiveness Data and Information Set (HEDIS®) data into the PFV Quality Navigator Tool (Qnav®).
Quality and Population Health Expert to Serve on Coordinating Committee and Chair Physical and Mental Health Technical Expert Panel
February 2, 2017 – New York, NY – Precision for Value, the market leader supporting global pharmaceutical companies in demonstrating the value of innovative medical products, today announced that Maureen Hennessey, SVP, Director, Quality and Population Health Systems, has been appointed to the National Quality Forum’s (NQF) Medicaid Innovation Accelerator Project 2016-2017 (IAP). She will serve on the multi-stakeholder coordinating committee and as chair of the technical expert panel (TEP) supporting physical and mental health integration.
Precision for Value’s Dan Renick returns to Managed Healthcare Executive to examine potential healthcare policies in the new Trump administration.
Precision for Value president Dan Renick discusses the fallout from the recently blocked merger between Aetna and Humana, in the latest edition of Managed Healthcare Executive.
Section 114 of the Food and Drug Administration Modernization Act of 1997 (FDAMA) was designed to allow pharmaceutical manufacturers to share health economic information with payers. This study shows how, by working in partnership with a pharmaceutical manufacturer, our scientists assessed COPD-related outcomes based on administrative claims data among combination therapy–naive patients—and enabled the client to engage payers on the benefits of its treatment.
Tapping Former Payer Decision Makers Brings Unrivaled Insights to Clients
January 5, 2017 – New York, NY – Precision for Value, the market leader in supporting global pharmaceutical and life sciences companies in demonstrating the value and outcomes of innovative medical products, today announced major additions to its Payer Strategy Team with the hiring and promotion of several key executives.
Addressing the pharmaceutical industry’s urgent need to leverage real-world market insights in response to growing government and payer scrutiny over drug pricing and access, Precision for Value (Precision) has strategically assembled an industry-leading team of former payer decision makers with a direct understanding of the evolving drug marketplace, as well as strong ties to their current industry counterparts. By understanding how payers measure value and the supporting evidence, Precision has helped dozens of clients secure desired levels of market access for their innovative medical treatments.
Precision is proud to announce that PHE scientific advisor Anupam Jena, MD has been named by Becker’s Hospital Review as one of the 60 most powerful people in healthcare in 2016, joining other influential leaders such as Robert Califf, Frances Collins, David Feinberg, Bill & Melinda Gates, Barack Obama, and Donald Trump. Included in their annual list, Dr. Jena was recognized in part for his study published this year in JAMA that found female physicians at some of the nation’s most prominent public medical schools earn nearly $20,000 less a year on average than their male colleagues.
Congratulations, Dr. Jena!
New Office Space at One Grand Central Place Bolsters Square Feet to Nearly 18,000
December 8, 2016 – New York, NY – Precision for Value, the market leader in supporting global pharmaceutical and life sciences companies in achieving commercial excellence, announced the move of its New York City office into a larger location in midtown Manhattan to accommodate rapid growth and an expanding workforce. The office will now be located in One Grand Central Place at 60 East 42nd Street. The nearly 18,000 square foot space will be home to over 80 employees.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
